155 related articles for article (PubMed ID: 8192114)
1. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.
Rook AH; Prystowsky MB; Cassin M; Boufal M; Lessin SR
Arch Dermatol; 1991 Oct; 127(10):1535-40. PubMed ID: 1929461
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
8. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
10. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
11. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
13. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.
Richardson SK; Lin JH; Vittorio CC; Kim EJ; Yoon JS; Junkins-Hopkins J; Rook AH
Clin Lymphoma Myeloma; 2006 Nov; 7(3):226-32. PubMed ID: 17229339
[TBL] [Abstract][Full Text] [Related]
14. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
15. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
[No Abstract] [Full Text] [Related]
16. A prospective study on the evolution of the T-cell repertoire in patients with Sézary syndrome treated by extracorporeal photopheresis.
Ingen-Housz-Oro S; Bussel A; Flageul B; Michel L; Dubertret L; Kourilsky P; Gachelin G; Bachelez H; Musette P
Blood; 2002 Sep; 100(6):2168-74. PubMed ID: 12200382
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis in the red man or pre-Sézary syndrome.
Zachariae H; Bjerring P; Brodthagen U; Søgaard H
Dermatology; 1995; 190(2):132-5. PubMed ID: 7727834
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
19. Management of cutaneous T-cell lymphoma: The future is here.
Wood GS
J Am Acad Dermatol; 2001 Aug; 45(2):317. PubMed ID: 11464201
[No Abstract] [Full Text] [Related]
20. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
